Xhance, a drug marketed by Optinose US Inc, has fourteen patents. It has a total of 293 patent family members spanning across 29 countries. The generic ingredient in Xhance is fluticasone propionate, which has one listed supplier.
Security agencies warn of heightened threat to critical national infrastructure
The NCSC and CISA warn that pro-Russia hacktivists are focusing on vulnerable industrial control systems, posing a serious cybersecurity threat.